Effects of a Cognitive Training Program on Chemotherapy-induced Cognitive Impairment (Chemobrain) in Breast Cancer Patients Undergoing Active Treatment
Launched by UNIVERSITY OF SALAMANCA · Nov 11, 2024
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a special cognitive training program can help breast cancer patients who are experiencing difficulties with thinking and memory, often referred to as "chemobrain." As more people survive breast cancer thanks to better treatments, it’s important to address these cognitive issues that can affect daily life. The trial will involve 50 adults with newly diagnosed breast cancer who are starting their treatment. Participants will be divided into two groups: one will receive cognitive training activities designed to improve everyday thinking, while the other group will receive only educational materials about managing cognitive decline.
To join the study, participants must be at least 18 years old, recently diagnosed with breast cancer, and able to handle daily tasks independently. They also need to be willing to participate and complete the study requirements. Throughout the trial, participants can expect to take part in various cognitive exercises over four months, with evaluations before and after the program to see how well it works. By understanding the impact of cognitive training, researchers hope to create helpful strategies for breast cancer patients dealing with cognitive challenges during their treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being an adult (18 years or older). Having a recent histopathological diagnosis of newly diagnosed breast cancer and starting oncological treatment.
- • Being fully capable of performing daily functions. Willingness to voluntarily participate in the study and signing the informed consent.
- Exclusion Criteria:
- • Lack of literacy skills or significant language comprehension deficit. Diagnosis of a Central Nervous System tumor or participation in another cognitive stimulation program.
- • Clinical diagnosis of a neurocognitive disorder as defined in the DSM-V.
- Withdrawal Criteria:
- • Dropping out of the program or not completing the final evaluation.
About University Of Salamanca
The University of Salamanca, one of the oldest and most prestigious universities in Spain, is a leading institution in academic research and clinical trials. With a strong commitment to advancing healthcare and medical science, the university engages in innovative research initiatives that address critical health challenges. Its clinical trial programs are characterized by rigorous scientific methodology, interdisciplinary collaboration, and a focus on ethical standards, ensuring high-quality outcomes that contribute to the advancement of medical knowledge and patient care. The University of Salamanca fosters partnerships with healthcare professionals and industry leaders, positioning itself at the forefront of clinical research and education.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported